A large proportion of B and T cell origin ALL, Non-Hodgkins Lymphoma (NHL) and CLL cell lines were particularly sensitive to AKT inhibition (Figure 1B, Figure 2B). The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.